Annovis Bio Inc. announced on January 14, 2025, that it was granted a U.S. patent covering methods for the treatment and prevention of acute brain or nerve injuries using buntanetap. The U.S. Patent and Trademark Office (USPTO) issued this patent on January 2, 2025, under publication number US-2025-0000846-A1. This patent is based on buntanetap’s ability to reduce neurotoxicity and mitigate neurodegenerative processes.
This newly issued patent expands buntanetap's potential applicability to conditions such as stroke, ischemia, traumatic brain injury, and micro infarcts. The patent has already been granted in the EU, Japan, and worldwide, meaning the company now holds global protection for this use. This significantly broadens the potential market for buntanetap beyond its primary indications.
Maria Maccecchini, Ph.D., CEO of Annovis, stated that this patent adds to their growing intellectual property portfolio. It further expands the possible applications of buntanetap beyond Alzheimer’s and Parkinson’s diseases. This development highlights the versatility of buntanetap's mechanism of action.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.